The specific $8.48m figure you mentioned doesn’t appear in the search results, but there has been a significant and ongoing pattern of Millstreet Capital selling Diebold Nixdorf (NYSE: DBD) stock. Here’s what the filings show:
Millstreet Capital’s recent DBD sell-down (2026)
On April 8, 2026, Millstreet-advised accounts sold 399,929 shares at an average price of $82.42 per share, leaving 4,816,743 shares indirectly held. Stocktitan
On April 15–16, 2026, Millstreet sold a further 112,305 shares at prices ranging from $84.77 to $85.43, totaling approximately $9.55 million. After those transactions, Millstreet indirectly held 4,704,438 shares. Investing.com
On June 8, 2026, accounts advised by Millstreet sold 88,334 shares at $82.99 per share, totaling approximately $7.33 million. Following the sale, they collectively held 4,616,104 shares. Investing
On June 10–11, 2026, a further 18,768 shares were sold at prices between $82.06 and $82.08, totaling approximately $1.54 million, leaving the group with 4,597,336 shares. Investing.com
On June 12 and 15, 2026, Millstreet-advised accounts sold another 161,440 shares at average prices of $82.12 and $83.91 respectively, with 4,435,896 shares remaining after the transactions. Stocktitan
Most recently, on June 24–25, 2026, Millstreet sold 231,464 shares — 228,723 at $83.95 on June 24 and 2,741 at $85.06 on June 25 — while still retaining an indirect position of over 4.2 million shares. Stock Titan
Context on DBD
Despite the steady sell-down, the stock has delivered a strong 60% return over the past year, and InvestingPro analysis suggests it remains undervalued at current levels with a “GREAT” financial health score. Diebold Nixdorf reported Q1 2026 EPS of $0.67, beating the $0.62 consensus estimate — an ~81% year-over-year EPS growth — with revenue of $891.8 million. InvestingInvesting.com
The $8.48m sale you referenced may relate to one of the multi-day tranches above or a filing not yet indexed. Would you like me to search for a more specific date or filing?
